http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021180818-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3b4f2ef8f062dcde3a2b7cd81748472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed3c2f63a5b1c705b1b389a6f1f1f7c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea8dafc6f989f3637bf89024e2bb24d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df02dc2eab1779ebc7dfb5accf94318b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate | 2021-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59036256394a06e9740200113e242329 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e85730ed2a108b86bc892cdd2e34517e |
| publicationDate | 2021-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021180818-A1 |
| titleOfInvention | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| abstract | Central Serous chorioretinopathy (CSCR) is primarily an ocular disease, affecting the choroid and the retinal pigment epithelium. To date, no systemic biomarker of CSCR have been discovered that could link both forms and help the diagnosis in challenging cases. In the present invention, the inventors measure in European cohorts of CSCR patients (n=168) with (n=90) or without epitheliopathy (n=78) and a cohort of 153 control subjects without any ocular disease history, the serum levels of NGAL and the NGAL/MMP9 complex. Serum NGAL (ng/ml) was significantly higher in the control group (108.8±46.8) than in the CSCR cohort (80.4±46.4, p <0.0001). Serum NGAL (ng/ml) was significantly lower in the acute/ recurrent cohort (n=78, 71.3 ±32.1) than in the control and, than in the chronic cohort (n=90, 88.3±55, p=0.03). Similarly, Serum NGAL/MMP9 (ng/ml) levels was lower in the whole CSCR cohort (44.5±39.6) as compared to the controls (77.6±47.8, p<0.0001). Serum NGAL/MMP9 (ng/ml) were significantly lower in the acute/ recurrent cohort (37.6±37.9) than in the control and, than in the chronic cohort (50.5±40.3, p=0.002). Thus, in both forms of CSCR serum NGAL and NGAL/MMP9 are lower than in the control population, providing a biological link between the two forms and a potential susceptibility to oxidative stress and innate immune dysregulation. Systemic LCN2 being elevated in other retinal diseases, it represents a specific biomarker for CSCR. |
| priorityDate | 2020-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.